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USD868.3 for EAC and RAC groups respectively. The overall
cost/patient for H. pylori eradication was USD849 and USD
847.3 for EAC and RAC groups respectively. No signiﬁcant
adverse effects were experienced by patients in either group and
hence cost incurred in this area was minimal. CONCLUSION:
Esomeprazole and rabeprazole triple therapies appear to have
similar effectiveness in H. pylori eradication in patients with
non-ulcer dyspepsia. Rabeprazole triple therapy may have cost
savings when the whole population is considered.
INDIVIDUAL’S HEALTH
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OBJECTIVE: Different treatments are available for Atopic Der-
matitis care. The preferences of patients should be taken into
consideration in the development of treatment strategies. The
aim of this study is to establish patients’ preferences and their
willingness-to-pay (WTP) on different AD treatment options.
METHODS: The CODA study was a naturalistic, multicentre,
longitudinal ambispective (retro-prospective), prevalence based
Cost-of-Illness study. Data on patients with moderate or severe
AD enrolled during ﬂare-up were collected. A discrete-choice-
experiment (DCE) was applied to enrolled patients. The follow-
ing attributes were considered to be important after interviewing
20 patients: pharmaceutical formulation (water-based cream vs
oil-based cream), the delay of The rapeutic response (4hours vs.
24hours vs. 48 hours), duration of therapeutic response (1 week
vs. 4 weeks vs. 8 weeks), long-term side effects and local side
effects (possible vs no). In order to estimate the WTP we added
the out-of-pocket cost of treatment (€0 vs. €50 vs. €100/month).
RESULTS: One-hundred-and-one of the 104 enrolled patients
(males 53.8%, mean age = 32.9 ± 11.8) ﬁlled in the DCE ques-
tionnaire. All attributes, excluding pharmaceutical formulation,
were relevant in patients’ choice (P < 0.001). Since the attribute
“cost” is determinant in the choice, a monetary value can be
assigned to each other relevant attribute. The conditional-probit-
model demonstrated that patients are willing-to-pay per month:
€104 for a “8 weeks therapeutic response” compared with 1
week; €47 for a treatment with “no local side effects”; €45 for
a treatment with “no long term side effects”; €21 for a “thera-
peutic response delay” of just one day. CONCLUSIONS: To our
knowledge, our study is the ﬁrst to elicit patients’ preferences
and their WTP for AD treatment. This information can guide
clinicians and decision makers to plan optimal health care.
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OBJECTIVES: To test whether the health of the mothers is
affected by the presence of a disabled or chronically-ill child.
METHODS: Using the National Longitudinal Survey of Chil-
dren and Youth (1994–2000), a nationally representative house-
hold survey in Canada, ordered Probit analysis was used to test
the effect of the presence of a disabled child on self-reported
health, controlling for other factors. Firstly, we modeled the
health effect of a disabled child in the house currently. Secondly,
utilizing the longitudinal aspect of the data, we modeled the
effect of the presence of a disabled child: a) currently only; 
b) previous years only; and c) both currently and previously.
Married and lone mothers are analyzed separately for children
aged 6–15 years of age in 2000 for a sample size of 5217 and
1177 for married and lone mothers, respectively. Bootstrap stan-
dard errors were calculated to account for multi-staged, non-
random survey design. To cope with causal inference issues we:
1) control for previous health status, and 2) test results using
propensity score matching (PSM). RESULTS: Evaluating at the
sample means, model 1 indicates a shift down in the health dis-
tribution for mothers with disabled children. There is a lower
probability of excellent health of 10[8.8–11.2] percentage points
for married mothers with a disabled child compared to house-
holds with no disabled children. Lone mothers show a difference
of 9[7–11] percentage points although health for lone mothers
is lower in general compared to married mothers. Model 2 shows
the strongest association for those households with a disabled
child both currently and in the past. PSM analysis conﬁrms our
results. CONCLUSIONS: The presence of a disabled or chroni-
cally-ill child has a statistically signiﬁcant effect on the health of
mothers. Consequences for maternal health are larger in the
long-run, if the child’s condition persists.
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OBJECTIVE: Validating a German child-friendly version of 
the EuroQol (EQ-5D) in different patient samples. METHODS:
After the translation from the original English version and
pretesting in cognitive interviews with native speakers of the
target language, the questionnaire was tested in two patient
groups (obesity and CF) and a sample of healthy children
between the ages of 8 and 16. For the validation three validated
instruments which measure hrQol in children and adolescents
were utilized (KINDL, KIDSCREEN and ChildDynHA). T-Tests
were conducted to audit potential differences in the EQ-5D
scores depending on age and sex of the children. Descriptive sta-
tistics were used to summarize EQ-5D scores as well as scores
of the additional instruments. RESULTS: The correlation
between the EQ-5D and the other instruments was quite high
(0.46–0.61). The highest correlation was found in the mobility
dimension. The CF groups shows the highest rates of reported
problems (42%), the rates of children who report no poblems
are quite similar for the obese and the healthy children (25 versus
27). CONLUSIONS: This pilot study of the questionaire showed
that the German child-friendly version of the EQ-5D is a valid
and feasible instrument to measure hrQol.
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In line with international trends, methylphenidate prescriptions
in Germany have been growing 20-fold over the last decade. This
has contributed to concern about potentially inappropriate and
excessive psychostimulant treatment for youths. OBJECTIVE:
To clarify methylphenidate prescriptions for children and ado-
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lescents with ADHD, using the comprehensive medical claims
database of Nordbaden/Germany, covering an insured popula-
tion of 2.234 m (hereof, 468,000 children and adolescents) in
2003. METHODS: A total of 11,245 children and adolescents
with a diagnosis of ADHD (ICD-10-codes for “Hyperkinetic
Disorder”, F90.0, F90.1) were identiﬁed. For a retrospective
analysis of methylphenidate prescriptions by age, gender, and
comorbid conduct disorder, administrative data from the orga-
nization of licensed physicians (Kassenaerztliche Vereinigung) 
in Nordbaden/Germany were combined with data from the
regional vdak, an association of statutory sick funds. RESULTS:
For the regional population, methylphenidate treatment preva-
lence rates were approximately 1.7% (children) and 0.6% (ado-
lescents). Among those with a diagnosis of ADHD, 4.3% of
preschoolers (age 0–6) were administered methylphenidate.
Among children (age 7–12), 35.1% (95%-CI, 33.0%–37.1%)
were prescribed methylphenidate; in adolescents (age 13–19),
this rate increased to 46.2% (42.7%–49.8%). Across ADHD
groups analyzed, children with concomitant conduct disorder
(42.4%; 39.4%–45.5% versus 27.9%; 26.2%–29.7%), and
boys (34.4%; 32.6%–36.2% versus girls: 25.5%; 22.7%–
28.4%) were more likely to be treated with methylphenidate.
Very few patients (<1%) received higher doses than recom-
mended. Child and adolescent psychiatrists accounted for 35%
of methylphenidate prescriptions for patients with ADHD 
(pediatricians, 40%; general practitioners, 12%). During 2003, 
the number of deﬁned daily doses prescribed in Nordbaden
increased by a compound annual growth rate of 27%. CON-
CLUSIONS: Though methylphenidate prescriptions continued
to increase during 2003, the present data do not provide 
evidence for overuse. Of note, a limitation of administrative
database analyses is lack of information on the accuracy of diag-
noses.—The low rate of methylphenidate prescriptions for
preschoolers corresponds to clinical guidelines.
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OBJECTIVES: To estimate the cost-effectiveness of adding epti-
ﬁbatide to medical therapy (aspirin, heparin, thienopyridine) in
acute coronary syndrome patients undergoing percutaneous
coronary intervention (PCI; including stent procedures) who are
at high risk of subsequent myocardial infarction (MI), target
vessel revascularization (TVR) or cardiovascular death, from a
hospital perspective. METHODS: A Markov model was con-
structed to evaluate eptiﬁbatide (two i.v.-injections of 180 μg/kg,
followed by an i.v.-infusion of 2.0 μg/kg/min for 18–24 h) versus
placebo in addition to aspirin, heparin, and thienopyridine
(mostly clopidogrel, oral loading dose 300 mg) before PCI. The
model has 4 disease states (no event, post-MI, post-TVR, death),
two tunnel states (TVR, non-fatal MI) and runs for the expected
lifetime of the patient. Patient’s history of TVR and MI is
tracked. The effectiveness parameters were taken from the 1-year
ESPRIT clinical trial and extrapolated with an estimated Weibull
function. Direct medical costs in 2006 prices were considered
from a hospital perspective. Resource utilization was based on
hospital expert-elicited treatment patterns from three German
urban hospitals and was valued with averaged prices of these
hospitals. Utilities were derived from published literature. Future
costs and effects were discounted at 5%. RESULTS: When com-
pared to treatment with aspirin, heparin, and thienopyridine,
adding eptiﬁbatide before PCI renders incremental net savings of
€927 and provides an additional 0.06 QALY per patient. Simi-
larly, treating 1000 patients additionally with eptiﬁbatide before
PCI avoids 11 fatal and 44 non-fatal MIs, but leads to 7 addi-
tional TVRs due to increased survival. Were there no differences
in survival, eptiﬁbatide would avoid 45 non-fatal MIs and 1
TVR. These results are sensitive to the price and effectiveness of
eptiﬁbatide. CONCLUSIONS: Adding eptiﬁbatide before PCI in
the investigated patient population (at high risk of subsequent
MI, TVR and death) seems to substantially reduce hospital costs
and increase patient relevant health outcomes.
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OBJECTIVES: The current diagnostic management of patients
with palpitations sometimes fails to establish a diagnosis. The
aim of the Recurrent Unexplained Palpitations (RUP) study was
to compare the diagnostic yield and the costs of prolonged 
monitoring strategy using an implantable loop recorder (ILR)
with that of conventional diagnostic testing, in patients with
infrequent unexplained palpitations. METHODS: RUP is a mul-
ticentrer, prospective, randomized study. We studied 50 consec-
utive patients (mean age 55 ± 18 years, 33 females) without or
with only mild heart disease, and with clinically signiﬁcant, infre-
quent (>=1 episode per month), sustained (>1 minute) palpita-
tions. Before enrolment, patients had a negative initial evaluation
including ECG, 24 hour Holter monitoring, and blood chemistry
examinations. Enrolled patients were randomized either to con-
ventional strategy (n = 24) or to ILR implantation (n = 26). In
order to evaluate the cost-effectiveness of ILR strategy, full hos-
pital cost of procedures was calculated. RESULTS: In the con-
ventional testing group a diagnosis was obtained in 5 patients (1
atrial ﬁbrillation, 4 supraventricular tachycardia). In the ILR
group a diagnosis was obtained in 19 subjects (2 sinus rhythm,
6 supraventricular tachycardia, 4 sinus tachycardia, 4 atrial 
ﬁbrillation, 2 atrial ﬂutter, 1 paroxysmal AV block). Thus, the
diagnostic yield of ILR was signiﬁcantly higher respect to con-
ventional strategy (73% vs 21%, p < 0.001). The average cost
per patient was €1.410 in the conventional strategy group and
€2.233 in the ILR group (p < 0.001). Considering the total cost
for each group, the cost per diagnosis was €6.767 and €3.056
respectively. CONCLUSIONS: The ICER obtained is low if com-
pared to further examinations and acute events management nec-
essary in case of less of diagnosis. The results of cost-effectiveness
analysis could be useful to design further research protocols. Fur-
thermore, these results could help decision makers to allocate
resources based on cost-effectiveness evidences.
